The U.S. Securities and Exchange Commission has asked Pfizer Inc. for information about two of its painkillers, Celebrex and Bextra, the Associated Press reported Tuesday.

The company wouldn’t elaborate, except to say it is cooperating with the request, which was made in the second quarter of this year, the wire service said. Both drugs belong to a class of painkillers called cox-2 inhibitors, which also includes the Merck and Co. drug Vioxx.

Bextra and Vioxx have been withdrawn from U.S. markets after research linked them to higher rates of heart attack and stroke in long-term users.

Merck withdrew Vioxx September 30, 2004 and Pfizer pulled Bextra from pharmacy shelves in April, 2005.

Celebrex remains on the market but includes new warnings required by the U.S. Food and Drug Administration about possible cardiovascular risks.

We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.

pink pills on purple background
What is Celebrex? Celebrex is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs)....
gold pills
What is Bextra? Bextra is valdecoxib-based drug that is administered orally. Bextra is used as treatment...

Thank you for all your hard work

Thank you for all your hard work over the past years on my behalf and so many others. God bless you all.